- Home
- PETZ vs BRTX Comparison
PETZ vs BRTX Comparison
Compare PETZ & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PETZ | BRTX |
|---|---|---|
| Founded | 2002 | 1997 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Managed Health Care |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9M | 9.3M |
| IPO Year | 2017 | 2015 |
Fundamental Metrics
Financial Performance| Metric | PETZ | BRTX |
|---|---|---|
| Price | $1.16 | $0.24 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 5.7K | ★ 6.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 66.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | N/A | $24.64 |
| Revenue Next Year | N/A | $287.76 |
| P/E Ratio | $6.89 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.68 | $0.19 |
| 52 Week High | $1.68 | $2.10 |
Technical Indicators
Market Signals| Indicator | PETZ | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.23 | 30.10 |
| Support Level | $0.94 | $0.19 |
| Resistance Level | $1.20 | $0.29 |
| Average True Range (ATR) | 0.07 | 0.03 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 41.98 | 39.74 |
Price Performance
Historical ComparisonAbout PETZ TDH Holdings Inc.
TDH Holdings Inc is engaged in the business of manufacturing and selling pet food and restaurant operations. The company has two operating segments, which include Petfood sales and the Restaurant business. It has a focus on the Restaurant business segment and generates the majority of its revenue.
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.